DCC-2618
Phase 1Small molecule
DCC-2618 is one of 4 small molecule programs targeting Gastrointestinal Stromal Tumors. It is currently in Phase 1.
1
Indications
4
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Gastrointestinal Stromal Tumors
#DrugCompanyPhaseTrials
1Tasigna
AAzurity Pharmaceuticals
Approved
Stivarga
BayerPhase 2
Gleevec
NovartisPhase 2
DCC-2618
DDeciphera Pharmaceuticals, LLC
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Malignancies1 trial
Gastrointestinal Stromal Tumor1 trial
Advanced1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DCC-2618. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- DDeciphera Pharmaceuticals, LLC